| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | masitinib | GDSC1000 | pan-cancer | AAC | -0.07 | 0.03 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.073 | 0.03 |
| mRNA | TL-1-85 | GDSC1000 | pan-cancer | AAC | -0.065 | 0.03 |
| mRNA | tubastatin A | GDSC1000 | pan-cancer | AAC | -0.066 | 0.03 |
| mRNA | RDEA119 | GDSC1000 | pan-cancer | AAC | -0.065 | 0.03 |
| mRNA | AKT inhibitor VIII | GDSC1000 | pan-cancer | AAC | -0.073 | 0.03 |
| mRNA | Bryostatin 1 | GDSC1000 | pan-cancer | AAC | -0.074 | 0.03 |
| mRNA | HG-6-64-1 | GDSC1000 | pan-cancer | AAC | -0.072 | 0.03 |
| mRNA | QS11 | CTRPv2 | pan-cancer | AAC | -0.15 | 0.04 |
| mRNA | TAE684 | CCLE | pan-cancer | AAC | -0.093 | 0.04 |